

Lena Specht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5699009/publications.pdf>

Version: 2024-02-01

271
papers

20,644
citations

19636

61
h-index

10724

138
g-index

282
all docs

282
docs citations

282
times ranked

15955
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
2	A Prognostic Score for Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1506-1514.	13.9	1,553
3	Early Interim 2- ¹⁸ F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
4	FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 52-59.	0.6	694
5	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. <i>Lancet</i> , The, 2003, 362, 933-940.	6.3	626
6	Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2002, 20, 4448-4452.	0.8	536
7	A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. <i>Radiotherapy and Oncology</i> , 1998, 46, 135-146.	0.3	523
8	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 854-862.	0.4	479
9	Early Positron Emission Tomography Response—Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397
10	Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. <i>Radiotherapy and Oncology</i> , 2006, 79, 270-277.	0.3	363
11	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 11-31.	0.4	303
12	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 49-58.	0.4	259
13	Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography—Staged Treatment-Naive Patients With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4508-4514.	0.8	252
14	Osteoradionecrosis of the jaws: Clinical characteristics and relation to the field of irradiation. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1088-1093.	0.5	244
15	Surveillance following orchidectomy for stage I seminoma of the testis. <i>European Journal of Cancer</i> , 1993, 29, 1931-1934.	1.3	232
16	Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. <i>Radiotherapy and Oncology</i> , 2004, 72, 53-60.	0.3	231
17	Breathing adapted radiotherapy for breast cancer: Comparison of free breathing gating with the breath-hold technique. <i>Radiotherapy and Oncology</i> , 2005, 76, 311-318.	0.3	224
18	The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. <i>British Journal of Cancer</i> , 2012, 106, 1526-1534.	2.9	216

#	ARTICLE	IF	CITATIONS
19	RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE. <i>Lancet, The</i> , 1987, 330, 83-88.	6.3	198
20	Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. <i>Haematologica</i> , 2006, 91, 482-9.	1.7	198
21	Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. <i>British Journal of Cancer</i> , 2011, 104, 830-840.	2.9	182
22	The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. <i>Radiotherapy and Oncology</i> , 2011, 100, 49-55.	0.3	176
23	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. <i>Annals of Oncology</i> , 2006, 17, 1749-1760.	0.6	171
24	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 32-39.	0.4	150
25	The effect of different lung densities on the accuracy of various radiotherapy dose calculation methods: Implications for tumour coverage. <i>Radiotherapy and Oncology</i> , 2009, 91, 405-414.	0.3	147
26	Reduction of cardiac and pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1375-1380.	0.4	145
27	Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 521-529.	0.4	138
28	Deviations in delineated GTV caused by artefacts in 4DCT. <i>Radiotherapy and Oncology</i> , 2010, 96, 61-66.	0.3	136
29	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 794-808.	0.4	128
30	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. <i>Lancet Haematology, the</i> , 2015, 2, e492-e502.	2.2	123
31	Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. <i>Annals of Oncology</i> , 2013, 24, 2113-2118.	0.6	121
32	Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. <i>European Journal of Cancer</i> , 2017, 70, 75-82.	1.3	115
33	The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. <i>Radiotherapy and Oncology</i> , 2008, 88, 202-210.	0.3	113
34	Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2007, 78, 206-212.	1.1	111
35	Cardiovascular disease after cancer therapy. <i>European Journal of Cancer, Supplement</i> , 2014, 12, 18-28.	2.2	110
36	Minimizing Late Effects for Patients With Mediastinal Hodgkin Lymphoma: Deep Inspiration Breath-Hold, IMRT, or Both?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 169-174.	0.4	109

#	ARTICLE	IF	CITATIONS
37	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	2.9	109
38	A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000–2010: The largest registry-based study to date. <i>International Journal of Cancer</i> , 2015, 136, 2196-2203.	2.3	103
39	Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. <i>Radiotherapy and Oncology</i> , 2014, 111, 360-365.	0.3	102
40	Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. <i>Haematologica</i> , 2010, 95, 494-500.	1.7	93
41	Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. <i>Cancer</i> , 1988, 61, 1719-1727.	2.0	91
42	Risk of Developing Cardiovascular Disease After Involved-Node Radiotherapy Versus Mantle Field for Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1232-1237.	0.4	91
43	Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold. <i>Acta Oncologica</i> , 2015, 54, 60-66.	0.8	91
44	Risk factors for radiation-induced hypothyroidism. <i>Cancer</i> , 2011, 117, 5250-5260.	2.0	87
45	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. <i>Blood</i> , 2018, 132, 1635-1646.	0.6	86
46	Intra- and interfraction breathing variations during curative radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2007, 84, 40-48.	0.3	83
47	In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2705-2711.	0.8	83
48	Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. <i>Hematological Oncology</i> , 2006, 24, 146-150.	0.8	81
49	Three-dimensional MRI-linac intra-fraction guidance using multiple orthogonal cine-MRI planes. <i>Physics in Medicine and Biology</i> , 2013, 58, 4943-4950.	1.6	81
50	MiR-21 Expression in the Tumor Stroma of Oral Squamous Cell Carcinoma: An Independent Biomarker of Disease Free Survival. <i>PLoS ONE</i> , 2014, 9, e95193.	1.1	80
51	Oral complications in the head and neck radiation patient. <i>Supportive Care in Cancer</i> , 2002, 10, 36-39.	1.0	79
52	Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2012, 103, 69-75.	0.3	78
53	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. <i>Blood</i> , 2020, 135, 1829-1832.	0.6	78
54	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. <i>Annals of Oncology</i> , 2013, 24, 1344-1351.	0.6	75

#	ARTICLE	IF	CITATIONS
55	Evaluation of dose to cardiac structures during breast irradiation. <i>British Journal of Radiology</i> , 2011, 84, 743-746.	1.0	74
56	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. <i>Haematologica</i> , 2012, 97, 931-936.	1.7	73
57	Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients. <i>Oncotarget</i> , 2016, 7, 71761-71772.	0.8	73
58	Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 581-592.	0.4	73
59	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.4	71
60	The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. <i>Acta Oto-Laryngologica</i> , 2006, 126, 1096-1103.	0.3	68
61	Involved Node Radiation Therapy: An Effective Alternative in Early-Stage Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1057-1065.	0.4	68
62	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	0.4	67
63	Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 80, 257-262.	0.3	65
64	Need for Intensive Histopathologic Analysis to Determine Lymph Node Metastases When Using Sentinel Node Biopsy in Oral Cancer. <i>Laryngoscope</i> , 2008, 118, 408-414.	1.1	64
65	Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 138-143.	0.4	64
66	Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study. <i>Head and Neck</i> , 2016, 38, E1033-40.	0.9	63
67	Life years lost comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. <i>Cancer</i> , 2012, 118, 5432-5440.	2.0	61
68	Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1466-1470.	0.4	59
69	Hodgkin's disease and age*. <i>European Journal of Haematology</i> , 1989, 43, 127-135.	1.1	59
70	Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2000, 11, 845-849.	0.6	58
71	FDG-PET in the clinical management of Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 19-32.	2.0	55
72	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 76-80.	0.3	55

#	ARTICLE	IF	CITATIONS
73	Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study. <i>International Journal of Cancer</i> , 2016, 139, 2598-2605.	2.3	55
74	Artifacts in Conventional Computed Tomography (CT) and Free Breathing Four-Dimensional CT Induce Uncertainty in Gross Tumor Volume Determination. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1573-1580.	0.4	53
75	Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. <i>Acta Oncologica</i> , 2018, 57, 1143-1151.	0.8	52
76	Interfractional changes in tumour volume and position during entire radiotherapy courses for lung cancer with respiratory gating and image guidance. <i>Acta Oncologica</i> , 2008, 47, 1406-1413.	0.8	51
77	Increasing incidence of base of tongue cancers from 2000 to 2010 due to HPV: the largest demographic study of 210 Danish patients. <i>British Journal of Cancer</i> , 2015, 113, 131-134.	2.9	50
78	Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? â€œ Results from the randomized DAHANCA 5 and 7 trials. <i>Acta Oncologica</i> , 2011, 50, 1006-1014.	0.8	49
79	2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas. <i>Seminars in Radiation Oncology</i> , 2007, 17, 190-197.	1.0	48
80	Prognostic factors in Hodgkin's disease. <i>Seminars in Radiation Oncology</i> , 1996, 6, 146-161.	1.0	47
81	Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer. <i>Acta Oncologica</i> , 2013, 52, 1535-1542.	0.8	47
82	Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 335-342.e1.	0.2	47
83	Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. <i>Radiotherapy and Oncology</i> , 2017, 125, 41-47.	0.3	46
84	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	0.4	46
85	Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. <i>The Cochrane Library</i> , 2005, , CD003187.	1.5	45
86	Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. <i>Acta Oncologica</i> , 2007, 46, 214-220.	0.8	44
87	What's new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice?. <i>Cancer Imaging</i> , 2007, 7, 104-116.	1.2	44
88	Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival. <i>PLoS ONE</i> , 2014, 9, e110456.	1.1	44
89	Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 69-74.	2.8	44
90	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. , 2011, , CD007110.		43

#	ARTICLE	IF	CITATIONS
91	Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. <i>Cancer</i> , 1990, 65, 2594-2601.	2.0	41
92	Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 2007, 85, 24-28.	0.3	41
93	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , 2008, 80, 369-380.	1.1	41
94	The role of image guidance in respiratory gated radiotherapy. <i>Acta OncolÅ³gica</i> , 2008, 47, 1390-1396.	0.8	41
95	Geometric uncertainties in voluntary deep inspiration breath hold radiotherapy for locally advanced lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 510-514.	0.3	41
96	MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma. <i>Oral Oncology</i> , 2018, 83, 46-52.	0.8	41
97	Prognostic factors in Hodgkin's disease stage IV. <i>European Journal of Haematology</i> , 1988, 41, 359-367.	1.1	40
98	Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. <i>British Journal of Dermatology</i> , 2012, 166, 399-404.	1.4	40
99	Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 53-58.	0.4	39
100	Tumour burden as the main indicator of prognosis in Hodgkin's disease. <i>European Journal of Cancer</i> , 1992, 28, 1982-1985.	1.3	38
101	A Prospective, Open-Label Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1204-1207.	0.4	37
102	Ionizing Radiation Potentiates High-Fat Dietâ€™Induced Insulin Resistance and Reprograms Skeletal Muscle and Adipose Progenitor Cells. <i>Diabetes</i> , 2016, 65, 3573-3584.	0.3	35
103	First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 108.	0.7	35
104	Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 433-445.	0.4	34
105	Metal artefact reduction for accurate tumour delineation in radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 479-486.	0.3	34
106	Prognostic factors in Hodgkin's disease. <i>Cancer Treatment Reviews</i> , 1991, 18, 21-53.	3.4	33
107	Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy. <i>Lancet, The</i> , 1998, 351, 725-726.	6.3	33
108	DAHANCA 10 â€™ Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. <i>Radiotherapy and Oncology</i> , 2018, 127, 12-19.	0.3	32

#	ARTICLE	IF	CITATIONS
109	Incidence and survival of laryngeal cancer in Denmark: a nation-wide study from 1980 to 2014. <i>Acta Oncologica</i> , 2019, 58, 977-982.	0.8	32
110	Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study. <i>Oral Oncology</i> , 2011, 47, 546-551.	0.8	31
111	Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. <i>Acta Oncologica</i> , 2017, 56, 1204-1209.	0.8	31
112	The concept and evolution of involved site radiation therapy for lymphoma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 849-854.	1.0	30
113	Elective Nodal Irradiation and Patterns of Failure in Head and Neck Cancer After Primary Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 775-782.	0.4	30
114	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 501-512.	0.4	30
115	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	0.6	30
116	Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. <i>European Journal of Haematology</i> , 1989, 43, 45-49.	1.1	29
117	Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 64-69.	0.3	29
118	The Danish national guidelines for treatment of oral squamous cell carcinoma. <i>Acta Oncologica</i> , 2006, 45, 294-299.	0.8	28
119	Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. <i>European Journal of Haematology</i> , 1988, 41, 80-87.	1.1	27
120	Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark. <i>Acta Oncologica</i> , 2011, 50, 1199-1205.	0.8	27
121	Doses to Carotid Arteries After Modern Radiation Therapy for Hodgkin Lymphoma: Is Stroke Still a Late Effect of Treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 297-303.	0.4	27
122	The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. <i>Acta Oncologica</i> , 2013, 52, 1559-1565.	0.8	27
123	Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky053.	1.4	27
124	Construction of a pathological risk model of occult lymph node metastases for prognostication by semi-automated image analysis of tumor budding in early-stage oral squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18227-18237.	0.8	27
125	Deep inspiration breath hold radiotherapy for locally advanced lung cancer: Comparison of different treatment techniques on target coverage, lung dose and treatment delivery time. <i>Acta Oncologica</i> , 2013, 52, 1582-1586.	0.8	26
126	Failure-probability driven dose painting. <i>Medical Physics</i> , 2013, 40, 081717.	1.6	26

#	ARTICLE	IF	CITATIONS
127	Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2015, 54, 1408-1415.	0.8	26
128	Lymphocyte Count Kinetics, Factors Associated with the End-of-Radiation-Therapy Lymphocyte Count, and Risk of Infection in Patients with Solid Malignant Tumors Treated with Curative-Intent Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 812-823.	0.4	26
129	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1064-1081.	0.4	26
130	The prevalence of occult metastases in nonsentinel lymph nodes after stepwise serial sectioning and immunohistochemistry in cNO oral squamous cell carcinoma. <i>Laryngoscope</i> , 2011, 121, 294-298.	1.1	25
131	A Decade of Comparative Dose Planning Studies for Early-Stage Hodgkin Lymphoma: What Can We Learn?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1126-1135.	0.4	25
132	Incidence and survival in sinonasal carcinoma: a Danish population-based, nationwide study from 1980 to 2014. <i>Acta Oncologica</i> , 2018, 57, 1152-1158.	0.8	25
133	Deep inspiration breath hold in locally advanced lung cancer radiotherapy: validation of intrafractional geometric uncertainties in the INHALE trial. <i>British Journal of Radiology</i> , 2019, 92, 20190569.	1.0	25
134	The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 1992, 12, 217-229.	2.0	24
135	Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the International Database on Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 805-811.	0.4	23
136	Can audio coached 4D CT emulate free breathing during the treatment course?. <i>Acta Oncologica</i> , 2008, 47, 1397-1405.	0.8	23
137	Erosive potential of saliva stimulating tablets with and without fluoride in irradiated head and neck cancer patients. <i>Radiotherapy and Oncology</i> , 2009, 93, 534-538.	0.3	23
138	PET/CT in Radiation Therapy Planning. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 67-75.	2.5	23
139	Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?. <i>Acta Oncologica</i> , 2008, 47, 451-457.	0.8	22
140	Stability of percutaneously implanted markers for lung stereotactic radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 187-195.	0.8	20
141	Deep inspiration breath-hold radiotherapy for lung cancer: impact on image quality and registration uncertainty in cone beam CT image guidance. <i>British Journal of Radiology</i> , 2016, 89, 20160544.	1.0	20
142	Incidence and survival of oropharyngeal cancer in Denmark: a nation-wide, population-based study from 1980 to 2014. <i>Acta Oncologica</i> , 2018, 57, 269-275.	0.8	20
143	Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. <i>Cancer Medicine</i> , 2020, 9, 3033-3042.	1.3	20
144	Follicular lymphoma of the ocular adnexal region: A nation-based study. <i>Acta Ophthalmologica</i> , 2015, 93, 184-191.	0.6	19

#	ARTICLE	IF	CITATIONS
145	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. <i>Acta Oncologica</i> , 2014, 53, 462-470.	0.8	18
146	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1274-1281.	0.9	18
147	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 144-152.	0.4	18
148	Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 4.	1.3	18
149	Total tumor burden in lymphoma – an evolving strong prognostic parameter. <i>British Journal of Radiology</i> , 2021, 94, 20210448.	1.0	18
150	Ovarian function in young women in long-term remission after treatment for Hodgkin's disease stage I or II. <i>Scandinavian Journal of Haematology</i> , 1984, 32, 265-270.	0.0	17
151	Prognostic significance of tumour burden in Hodgkin's disease PS I and II. <i>Scandinavian Journal of Haematology</i> , 1986, 36, 367-375.	0.0	17
152	A step and shoot intensity modulated technique for total body irradiation. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 10, 1-7.	0.6	17
153	Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival. <i>Radiotherapy and Oncology</i> , 2021, 158, 175-183.	0.3	17
154	Testicular function in young men in long-term remission after treatment for the early stages of Hodgkin's disease. <i>Scandinavian Journal of Haematology</i> , 1984, 33, 356-362.	0.0	16
155	Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II). <i>Stem Cells Translational Medicine</i> , 2022, 11, 478-489.	1.6	16
156	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. <i>Frontiers in Pediatrics</i> , 2021, 9, 774348.	0.9	15
157	Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. <i>Acta Oncologica</i> , 2015, 54, 1416-1422.	0.8	14
158	Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer. <i>Acta Oncologica</i> , 2016, 55, 1053-1056.	0.8	14
159	Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. <i>BMC Cancer</i> , 2018, 18, 640.	1.1	14
160	Feasibility of Multiparametric Positron Emission Tomography/Magnetic Resonance Imaging as a One-Stop Shop for Radiation Therapy Planning for Patients with Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1329-1338.	0.4	14
161	Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Seminoma Stage I Followed with Surveillance. <i>Acta Oncologica</i> , 2002, 41, 77-83.	0.8	13
162	Radiotherapy for Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 237-243.	1.0	13

#	ARTICLE	IF	CITATIONS
163	Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 24-28.	0.9	13
164	<p>The Copenhagen Oral Cavity Squamous Cell Carcinoma database: protocol and report on establishing a comprehensive oral cavity cancer database</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 733-741.	1.5	13
165	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	0.6	13
166	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. <i>British Journal of Cancer</i> , 2020, 123, 46-53.	2.9	13
167	Final Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk Patients with Aggressive CD20+ Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2008, 112, 1013-1013.	0.6	13
168	Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. <i>Radiotherapy and Oncology</i> , 2022, 166, 137-144.	0.3	13
169	PET/CT in head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1329-1333.	3.3	12
170	Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes. <i>Acta Oncol&Aacute;gica</i> , 2010, 49, 984-990.	0.8	12
171	Three&eacron;year follow&eacron;up of sentinel node&eacron;negative patients with early oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2014, 36, 1109-1112.	0.9	12
172	An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas. <i>Frontiers in Oncology</i> , 2018, 8, 206.	1.3	12
173	Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancer. <i>British Journal of Radiology</i> , 2018, 91, 20180236.	1.0	12
174	TEDDI: radiotherapy delivery in deep inspiration for pediatric patients &eacron; a NOPHO feasibility study. <i>Radiation Oncology</i> , 2018, 13, 56.	1.2	12
175	Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation &eacron; a case report and a review of the literature. <i>Acta Oncol&Aacute;gica</i> , 2020, 59, 1480-1487.	0.8	12
176	Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by... <i>Blood</i> , 2005, 106, 18-18.	0.6	12
177	A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2015, 114, 206-211.	0.3	11
178	The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort. <i>Acta Oncol&Aacute;gica</i> , 2015, 54, 1071-1075.	0.8	11
179	Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. <i>Acta Oncol&Aacute;gica</i> , 2017, 56, 608-613.	0.8	11
180	Development and validation of a cycle&eacron;specific risk score for febrile neutropenia during chemotherapy cycles 2&eacron;6 in patients with solid cancers: The CSR FENCE score. <i>International Journal of Cancer</i> , 2020, 146, 321-328.	2.3	11

#	ARTICLE	IF	CITATIONS
181	Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). <i>Cancers</i> , 2020, 12, 3110.	1.7	11
182	Radiation dose-painting with protons vs. photons for head-and-neck cancer. <i>Acta Oncologica</i> , 2020, 59, 525-533.	0.8	11
183	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. <i>Blood</i> , 2017, 130, 736-736.	0.6	11
184	A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. <i>Oral Oncology</i> , 2017, 74, 77-82.	0.8	10
185	Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study. <i>International Journal of Cancer</i> , 2017, 140, 2232-2245.	2.3	10
186	Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. <i>Scandinavian Journal of Haematology</i> , 1985, 35, 166-173.	0.0	9
187	Survival of head and neck cancer in Greenland. <i>International Journal of Circumpolar Health</i> , 2010, 69, 373-382.	0.5	9
188	Percutaneously implanted markers in peripheral lung tumours: Report of complications. <i>Acta Oncologica</i> , 2013, 52, 1225-1228.	0.8	9
189	Prescribing and evaluating target dose in dose-painting treatment plans. <i>Acta Oncologica</i> , 2014, 53, 1251-1256.	0.8	9
190	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2017, 56, 1562-1570.	0.8	9
191	Incidence and survival of hypopharyngeal cancer: a Danish Nation-Wide Study from 1980 to 2014. <i>Acta Oncologica</i> , 2019, 58, 1570-1576.	0.8	9
192	No changes in myocardial perfusion following radiation therapy of left-sided breast cancer: A positron emission tomography study. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1923-1932.	1.4	9
193	Risk factors for cardiovascular disease in 5-year survivors of adolescent and young adult cancer: A Danish population-based cohort study. <i>Cancer</i> , 2020, 126, 659-669.	2.0	9
194	Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2890-2897.	3.2	9
195	FDG-PET scan and treatment planning for early stage Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2007, 85, 176-177.	0.3	8
196	Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. <i>The Cochrane Library</i> , 2017, 4, CD007110.	1.5	8
197	Synchronous, bilateral tonsillar carcinomas: Patient characteristics and human papillomavirus genotypes. <i>Oral Oncology</i> , 2017, 74, 105-110.	0.8	8
198	A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. <i>Oral Oncology</i> , 2018, 81, 52-60.	0.8	8

#	ARTICLE	IF	CITATIONS
199	Preparing data for multiparametric PET/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. <i>Physica Medica</i> , 2019, 61, 1-7.	0.4	8
200	Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study. <i>Acta Oncologica</i> , 2020, 59, 879-887.	0.8	8
201	RootPainter3D: Interactive machine learning enables rapid and accurate contouring for radiotherapy. <i>Medical Physics</i> , 2022, 49, 461-473.	1.6	8
202	Hodgkin's disease and age. <i>European Journal of Haematology</i> , 1989, 43, 127-35.	1.1	8
203	Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 508-514.	0.4	7
204	Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer. <i>Head and Neck</i> , 2020, 42, 3161-3170.	0.9	7
205	Robustness and Generalizability of Deep Learning Synthetic Computed Tomography for Positron Emission Tomography/Magnetic Resonance Imaging-Based Radiation Therapy Planning of Patients With Head and Neck Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100762.	0.6	7
206	Impact of p16-overexpression on overall and progression-free survival outcomes in oral cavity squamous cell carcinomas: A semi-national, population-based study. <i>Oral Oncology</i> , 2020, 111, 105031.	0.8	6
207	Outcome-based multiobjective optimization of lymphoma radiation therapy plans. <i>British Journal of Radiology</i> , 2021, 94, 20210303.	1.0	6
208	The Feasibility of Implementing Deep Inspiration Breath-Hold for Pediatric Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 977-984.	0.4	6
209	Human papillomavirus and oropharyngeal cancer in Greenland in 1994–2010. <i>International Journal of Circumpolar Health</i> , 2013, 72, 22386.	0.5	5
210	Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 171-178.	0.6	5
211	Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome. <i>Radiotherapy and Oncology</i> , 2020, 150, 236-244.	0.3	5
212	Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 3319-3328.	1.0	5
213	Do We Need an Early Unfavorable (Intermediate) Stage of Hodgkin's Lymphoma?. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 881-896.	0.9	4
214	Improved prognosis for localized malignant lymphomas of the head and neck. <i>Acta Oto-Laryngologica</i> , 2010, 130, 626-631.	0.3	4
215	Radiotherapy for indolent lymphomas: how much is enough?. <i>Lancet Oncology</i> , The, 2014, 15, 372-374.	5.1	4
216	Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 279-281.	0.4	4

#	ARTICLE	IF	CITATIONS
217	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. <i>European Journal of Radiology</i> , 2021, 139, 109668.	1.2	4
218	Nimorazole may increase the effect of phenprocoumon. <i>Radiotherapy and Oncology</i> , 2005, 74, 345.	0.3	3
219	The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists. <i>Acta Oncologica</i> , 2008, 47, 150-151.	0.8	3
220	Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications. <i>EJNMMI Physics</i> , 2014, 1, A76.	1.3	3
221	Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose. <i>British Journal of Ophthalmology</i> , 2017, 101, 1206-1210.	2.1	3
222	Less mucositis toxicity after 6 versus 3 fractions of high-dose total body irradiation before allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1369-1371.	1.3	3
223	(18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivors. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 408-15.	1.0	3
224	Evaluation of methods for selecting the midventilation bin in 4DCT scans of lung cancer patients. <i>Acta Oncologica</i> , 2013, 52, 1715-1722.	0.8	2
225	Recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1069-1070.	0.6	2
226	In Reply to Scarpelli et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1396.	0.4	2
227	The risk of late effects following pediatric and adult radiotherapy regimens in Hodgkin lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 711-721.	1.0	2
228	Risk of bacterial, viral and fungal infections in patients with solid malignant tumors treated with curative intent radiation therapy.. <i>Advances in Radiation Oncology</i> , 2022, , 100950.	0.6	2
229	Hodgkin's disease: Recent concepts in classification and treatment. <i>European Journal of Haematology</i> , 1989, 42, 7-14.	1.1	1
230	Interim positron emission tomography in early stage Hodgkin lymphoma: is there evidence for its prognostic and predictive value in patients treated with standard combined modality treatment?. <i>Leukemia and Lymphoma</i> , 2013, 54, 1127-1128.	0.6	1
231	Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG14 Study)". <i>Oncologist</i> , 2014, 19, 91289-1289.		1
232	Editorial: Diffuse large B-cell lymphoma: survival of the fittest?. <i>European Journal of Haematology</i> , 2016, 96, 331-332.	1.1	1
233	On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer. <i>Acta Oncologica</i> , 2019, 58, 390-392.	0.8	1
234	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 977-978.	0.4	1

#	ARTICLE	IF	CITATIONS
235	Relapse localization in Danish pediatric patients with Hodgkin lymphoma. <i>Acta Oncologica</i> , 2021, 60, 658-666.	0.8	1
236	Iatrogenic cerebral radiation necrosis. <i>Practical Neurology</i> , 2021, 21, 427-430.	0.5	1
237	History of Radiotherapy of Hodgkin's Disease (Now Hodgkin Lymphoma). , 2011, , 1-6.		1
238	Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. , 2011, , 7-20.		1
239	Prognostic Factors. , 2011, , 97-115.		1
240	Different Histopathological Subtypes of Hodgkin Lymphoma Have Significantly Different Levels of FDG Uptake.. <i>Blood</i> , 2005, 106, 969-969.	0.6	1
241	Traditional and Modern Techniques for Radiation Treatment Planning. , 2011, , 123-151.		1
242	Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. <i>Blood</i> , 2011, 118, 2627-2627.	0.6	1
243	Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG). <i>Blood</i> , 2013, 122, 4292-4292.	0.6	1
244	Prognostic Factors. <i>Hematologic Malignancies</i> , 2015, , 131-155.	0.2	1
245	Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	1
246	A phase 2 trial of deep-inspiration breath hold in radiotherapy of gastric lymphomas. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 137-141.	1.2	1
247	Response Evaluation Following Radiation Therapy With 18F-FDG PET/CT: Common Variants of Radiation-Induced Changes and Potential Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 681-706.	2.5	1
248	In response to Dr. Remouchamps. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1206.	0.4	0
249	Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy. <i>Cancer Treatment Reviews</i> , 2004, 30, 479-482.	3.4	0
250	Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept. , 2011, , 91-122.		0
251	OP182. <i>Oral Oncology</i> , 2013, 49, S72-S73.	0.8	0
252	FDG-PET and radiotherapy in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 321-330.	1.1	0

#	ARTICLE	IF	CITATIONS
253	In Reply to Gunn and Garden. International Journal of Radiation Oncology Biology Physics, 2016, 96, 240-241.	0.4	0
254	Correlation between HPV status at T and N sites of oropharyngeal squamous cell carcinomas. Acta Oto-Laryngologica, 2017, 137, 1260-1264.	0.3	0
255	1549. Development and Validation of a Cycle-Specific Risk Score for Febrile Neutropenia After Chemotherapy in Patients with Cancer: The CSR FENCE Score. Open Forum Infectious Diseases, 2018, 5, S481-S481.	0.4	0
256	[OA141] Preparing data for multiparametric PET/MRI: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of 18F-FDG-PET uptake and diffusion weighted MRI in head/neck cancer. Physica Medica, 2018, 52, 54.	0.4	0
257	Early-stage mantle cell lymphoma – a rare entity with special characteristics and needs for treatment. Annals of Hematology, 2020, 99, 2963-2964.	0.8	0
258	Cardiac Lymphoma, a Challenging Extranodal Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 106, 463.	0.4	0
259	Baseline FDG PET/CT in free breathing versus deep inspiration breath-hold for pediatric patients with mediastinal lymphoma. Acta Oncologica, 2022, 61, 239-246.	0.8	0
260	Role of Radiotherapy. Hematologic Malignancies, 2021, , 51-64.	0.2	0
261	Early Results of a Phase II Trial Testing Low Dose Total Body Irradiation (LTBI) after Chemoimmunotherapy in Elderly High Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2007, 110, 1296-1296.	0.6	0
262	Future Prospects for Radiotherapy for Hodgkin Lymphoma. , 2011, , 205-210.		0
263	Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. , 2011, , 161-166.		0
264	Proton Therapy for Hodgkin Lymphoma. , 2011, , 197-203.		0
265	Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation. Medical Radiology, 2014, , 287-323.	0.0	0
266	Molecular profiling of tumour budding to implicate TGF- β 2 mediated epithelial-mesenchymal transition as a therapeutic target.. Journal of Clinical Oncology, 2015, 33, 6059-6059.	0.8	0
267	Diffuse Large B-Cell Lymphoma. , 2017, , 29-43.		0
268	The contribution of pre-existing cardiovascular (CV) risk factors to the risk of stroke or heart attack among non-Hodgkin lymphoma (NHL) survivors.. Journal of Clinical Oncology, 2017, 35, 10082-10082.	0.8	0
269	Prognostic Factors. Hematologic Malignancies, 2020, , 145-169.	0.2	0
270	252. Increased incidence rates of positive blood cultures shortly after chemotherapy treatment initiation among individuals treated for solid malignant tumours. Open Forum Infectious Diseases, 2020, 7, S125-S126.	0.4	0

#	ARTICLE	IF	CITATIONS
271	PET for radiotherapy planning. , 2022, , .		0